Mirum Pharmaceuticals (MIRM) CEO Christopher Peetz receives new equity awards

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. CEO and director Christopher Peetz reported new equity awards, including stock options and stock units granted on January 28, 2026. He received stock options for 67,000 shares at an exercise price of $100.85, vesting over four years starting one year after the vesting commencement date.

Peetz was also granted 43,500 restricted stock units, vesting in three equal annual installments on each anniversary of January 28, 2026. In addition, 75,000 previously granted performance restricted stock units had their performance criteria confirmed as met; two-thirds of these shares vest on March 15, 2026 and one-third on March 15, 2027. All reported derivative holdings are listed as directly owned.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Peetz Christopher

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	67,000	$0.00	--
Grant/Award	Restricted Stock Units	43,500	$0.00	--
Grant/Award	Performance Restricted Stock Units	75,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 67,000 shares (Direct); Restricted Stock Units — 43,500 shares (Direct); Performance Restricted Stock Units — 75,000 shares (Direct)

Footnotes (1)

1/4th of the shares vest one year after January 28, 2026 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 28, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. On January 23, 2024, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 28, 2026, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.

Form 4 Insider Transactions: What Each Field Means →

01/30/2026 - 06:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peetz Christopher

(Last)

(First)

(Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY

94404

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$100.85	01/28/2026		A		67,000		⁽¹⁾	01/27/2036	Common Stock	67,000	$0	67,000	D
Restricted Stock Units	⁽²⁾	01/28/2026		A		43,500		⁽³⁾	⁽³⁾	Common Stock	43,500	$0	43,500	D
Performance Restricted Stock Units	⁽²⁾	01/28/2026		A		75,000		⁽⁴⁾	⁽⁴⁾	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. 1/4th of the shares vest one year after January 28, 2026 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

3. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 28, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

4. On January 23, 2024, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 28, 2026, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.

	/s/ Judit Ryvkin, Attorney-in-Fact	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Mirum (MIRM) CEO Christopher Peetz report on January 28, 2026?

Christopher Peetz reported new stock options and stock units granted on January 28, 2026. These include 67,000 stock options, 43,500 restricted stock units, and 75,000 performance restricted stock units with performance criteria already met and scheduled vesting dates in 2026 and 2027.

How do Christopher Peetz’s new Mirum (MIRM) stock options vest?

The 67,000 stock options vest over four years from the vesting commencement date of January 28, 2026. One-quarter vests one year after that date, and the remaining three-quarters vest in 36 equal monthly installments starting from the first anniversary of the vesting commencement date.

What is the vesting schedule for Mirum (MIRM) CEO’s 43,500 restricted stock units?

The 43,500 restricted stock units granted to Christopher Peetz vest in three equal annual installments. One-third vests on each anniversary of January 28, 2026, so the entire award will be fully vested on the three-year anniversary of the vesting commencement date.

When do Christopher Peetz’s Mirum (MIRM) performance restricted stock units vest?

The 75,000 performance restricted stock units were granted in January 2024 and had performance criteria confirmed as met on January 28, 2026. Two-thirds of the shares vest on March 15, 2026, and the remaining one-third vest on March 15, 2027, subject to that schedule.

What does each Mirum (MIRM) restricted stock unit reported by the CEO represent?

Each restricted stock unit reported for Christopher Peetz represents a contingent right to receive one share of Mirum’s common stock. Actual receipt depends on satisfying the stated vesting schedules and, for the performance units, the already-determined achievement of specified performance criteria as outlined in the award terms.

Are Christopher Peetz’s reported Mirum (MIRM) equity awards held directly or indirectly?

The filing lists all reported derivative securities, including stock options, restricted stock units, and performance restricted stock units, as directly owned by Christopher Peetz. There are no footnote disclosures indicating indirect ownership through other entities or any disclaimers of beneficial ownership.